This retrospective study aims to perform a medication risk stratification using drugclaims data and to simulate the impact of the addition of various repurposed drugs on theMedication Risk Score (MRS) in a health insurance population. Our clinical tool wouldenable us to identify potential multi-drug interactions and potentially reduce the riskof adverse drug events (ADE) developing in these patients infected with COVID-19.
Certain investigational agents have been described in observational series or are being
used anecdotally based on in vitro or extrapolated evidence. It is important to
acknowledge that there are no controlled data supporting the use of any of these agents,
and their efficacy for COVID-19 is unknown. FDA-approved drugs such as
chloroquine/hydroxychloroquine, lopinavir/ritonavir, monoclonal IL-6 antibodies, JAK
inhibitors, thalidomide, and the new investigational drug remdesivir, have been proposed
for repurposing to fight COVID-19 and its complications.
A medication risk stratification strategy will be used to simulate the impacts of
different potential repurposed drugs for COVID-19 and the Medication Risk Score (MRS)
which is used as a predictive tool for ADEs. A retrospective study will be conducted
using de-identified drug claims data for commercially insured patients.
Inclusion Criteria:
- Patients enrolled with Cambia Health Solutions; Medicare/Medicaid or Commercial
Health Insurance Plan
- Patients with drug claims available from 10/01/2018 to 10/31/2019
Exclusion Criteria:
- Patients with no drug claims available for 2018
- Health Plan for injectable drugs
Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute
Orlando, Florida, United States
Veronique Michaud, Principal Investigator
Tabula Rasa HealthCare